MARIDEBART CAFRAGLUTIDE

UNII:	Z24U3U73HN
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	MARIDEBART CAFRAGLUTIDE
GSRS Full Record:	Z24U3U73HN i

2760218-55-9
AMG 133
AMG-133
Immunoglobulin G1, anti-(glucose-dependent insulinotropic polypeptide receptor) [275-cysteine,295-cysteine,300-glycine,305-cysteine] (human γ1-chain), disulfide with human κ-chain, dimer
Immunoglobulin G1, anti-(glucose-dependent insulinotropic polypeptide receptor) [275-cysteine,295-cysteine,300-glycine,305-cysteine] (human γ1-chain), disulfide with human κ-chain, dimer, 275,275′-bis(thioether) with 7-37-glucagon-like peptide I [8-(2-methylalanine),16-tyrosine,22-glutamic acid,36-glycine] (human) fusion protein with peptide linker ((GGGGS)3-N6-(2-mercaptoacetyl)lysinamide)
Immunoglobulin G1-kappa, anti-[Homo sapiens GIPR (gastric inhibitory polypeptide receptor)], Homo sapiens monoclonal antibody; gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV3-33*01 (92.9%)-(IGHD) -IGHJ4*01 (100%), CDRIMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, G1v64 CH2 C36, G1v54-30 CH2 C83, G84.4, C85 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 E36>C (275), R83>C (295), N84.4>G (300), V85>C (305) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain Homo sapiens (1'-214') [VKAPPA (Homo sapiens IGKV3-15*01 (97.9%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27-32.51-53.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
MARIDEBART CAFRAGLUTIDE [USAN]
Maridebart Cafraglutide
gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV3-33*01 (92.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, G1v64 CH2 C36, G1v54-30 CH2 C83, G84.4, C85 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 E36>C (275), R83>C (295), N84.4>G (300), V85>C (305) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-15*01 (97.9%)-IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27-32.51-53.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa; 275,275''-bis(thioether) conjugated to a glucagon-like peptide 1(GLP-1) analogue (GCG (glucagon) 98-126, GLP-1 7-35 A8>methylalanine (2), V16>Y (10), G22>E (16)), via a fused 18-mer linker (diglycyl- tris(tetraglycyl-seryl)-lysinamide
maridebart cafraglutide [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

MARIDEBART CAFRAGLUTIDE

Synonyms and Mappings

Resources